Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enalapril for Prevention of Chemotherapy-induced Cardiotoxicity
NCT00292526Phase 4Completed
- Sponsor
- European Institute of Oncology
- Start
- Nov 2000
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enalapril in chemotherapy-induced cardiotoxicity (CIC), sponsored by European Institute of Oncology. Primary endpoint: Incidence of chemotherapy-induced cardiotoxicity at 12 months. Started Nov 2000; status: completed.
02
Drugs
enalapril
03
Conditions
chemotherapy-induced cardiotoxicity (CIC)
Beyond the preview
Go deeper on NCT00292526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292526.